On April 18, 2023, the Hurun Institute officially released the Global Unicorn Index 2023 at the 9th China (Guangzhou) Annual Investment Conference & the Global Unicorn CEO Conference 2023 hosted in Guangzhou. Yuanxin Technology has been listed as a Global Unicorn Enterprise for three consecutive years with its comprehensive capability regarding medical services. As one of the healthcare technology companies on the list, Yuanxin Technology (Yuanxin) has been continuously improving the overall revenue, optimizing business structure and adding industrial value. According to data from Frost & Sullivan, by 2021, Yuanxin has become China's largest offline and online healthcare delivery platform focusing on prescription drugs by revenue, and it has a broad prospect for development in the subdivided track.

On April 26, the 2023 CHC · CITIC Securities Healthcare Conference and the 12th China Healthcare Investment CEO Conference were held, at which the 2022 China Healthcare Industry Investment and Financing Honor List was jointly launched. As the authoritative list that leads the trend of investment and financing in China's medical and healthcare industry, the list has selected a total of 14 awards in four categories namely investment institutions, enterprises, investors, and law firms. Yuanxin Technology topped the “2022 Most Influential Companies in Healthcare TOP 50” with its outstanding annual market performance and industry influence.

On May 25, 2023, Source Code Capital's portfolio company, Edianyun (02416. HK), a technology-enabled office IT service provider, was successfully listed on HKEX (02416. HK) at an offering price of HKD 9.46 per share. The closing price of the first day of listing closed at HKD 9.88 per share, and the company's market capitalization exceeded more than HKD 5 billion.

Technological Enterprise Services

Gaorong Capital's portfolio company, AaltoSemi, a high-end package substrate supplier, announced the completion of a Series A1 round of financing of over CNY 500 million. This round of financing was led by CTC Capital, with participation of Junhai Chuangxin, Lanhor Capital and other institutions. Other investors included the old shareholders Gaorong Capital, Kunqiao Capital and Summitview High-tech Venture Capital.

Another portfolio company of Gaorong Capital, Gravity XR, a manufacturer and solution provider focusing on R&D regarding XR chips, completed hundreds million yuan in a Series Pre-A+ round of financing. Investors included Goertek, PICO, MiHoYo, Zhongyuan Capital, Eastern Bell Capital, Eight Roads, Vipassana Fund, Ningbo Yongjiang Sci-Tech Innovation and Ningbo Zhenhai Fund.

Healthcare

Sherpa Capital’s portfolio company, Bliss Bio, an anti-cancer biopharmaceutical enterprise, completed a Series B++ round of financing which invested by Eisai. RedCloud Bio, a R&D company of new drugs for tumor resistance targets, completed nearly CNY 100 million in a Series B+ round of financing, jointly led by Lotus Lake Capital and Huayin Financial Investment. Sherpa Capital continued to participate in the investment.

Gaorong Capital's portfolio company, a R&D company of innovative drugs for metabolic diseases, Cholesgen, completed over CNY 100 million in a Series A round of financing, led by Gaorong Capital, with the participation of Great Filter Venture and other institutions.

In the 2nd quarter of 2023, Starquest Capital has been awarded a number of industry honors over the last three months.

On April 27, Outstanding and Outstanding Academy officially announced the release of the 3rd Annual List of China Institutional LP - 2022 China Outstanding Institutional LP Ranking at the 2023 China Outstanding Institutional LP Summit. This list, based on the performance in 2022 as the statistical year, recognizes the most active and outstanding LP institutions and individuals in 2022. Starquest Capital was awarded "China TOP 15 Best Market LP in 2022". Meanwhile, Frankie Fang, the founding managing partner, and James Jin, the partner of Starquest Capital, were respectively recognized as the "China TOP 30 Most Influential Investors in 2022" and the "China TOP 30 Outstanding Young Investors in 2022".

In June 2023, Starquest Capital published the latest ESG Investment Yearbook "The ESG Pathway 2022: Upholding Core Values, Fostering Future Growth". The book comprehensively analyzes the current state and emerging market trends of private equity responsible investment in China and around the world, meanwhile presenting an assessment methodology and multiple case studies.